BS_SXRS2P6T
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- age_years
- 3.2
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.686
- INTERFERON_GAMMA_RESPONSE+0.548
- IL6_JAK_STAT3_SIGNALING+0.500
- CHOLESTEROL_HOMEOSTASIS+0.474
- TNFA_SIGNALING_VIA_NFKB+0.445
- PROTEIN_SECRETION+0.443
- ALLOGRAFT_REJECTION+0.423
- ANDROGEN_RESPONSE+0.402
- COMPLEMENT+0.373
- INFLAMMATORY_RESPONSE+0.365
Top 10 suppressed
- E2F_TARGETS-0.440
- G2M_CHECKPOINT-0.414
- SPERMATOGENESIS-0.285
- MITOTIC_SPINDLE-0.156
- MYC_TARGETS_V1-0.155
- PANCREAS_BETA_CELLS-0.149
- APICAL_SURFACE-0.096
- DNA_REPAIR-0.075
- NOTCH_SIGNALING-0.067
- KRAS_SIGNALING_DN-0.042
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VW85Q4XJ | low-grade glioma | — | 0.923 |
| 2 | BS_CB6VK7PB | pilocytic astrocytoma | — | 0.918 |
| 3 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.910 |
| 4 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.909 |
| 5 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.907 |
| 6 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.903 |
| 7 | BS_E94QRJDW | low-grade glioma | — | 0.900 |
| 8 | BS_S1KK7XRH | low-grade glioma | — | 0.898 |
| 9 | BS_MF9X3PKH | low-grade glioma | — | 0.896 |
| 10 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.686 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.548 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.474 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.445 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.443 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.423 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.402 | Inavolisib | — uncovered |
| COMPLEMENT | 0.373 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.365 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.305 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.305 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.297 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.287 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.269 | Idelalisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.244 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.239 | Temsirolimus | — uncovered |